Overview

This 54-topic program covers data supporting guidelines, recommendations, and recent advances regarding therapeutic options for patients with solid tumors and hematologic disorders. After completing the program, learners will have a deeper understanding of the pathogenesis, diagnostic evaluation, and therapeutic modalities available for a breadth of solid tumors and hematologic disorders. The material can be used to help prepare attendees for certifying and re-certifying exams.

Learning Objectives

1. Describe the pathogenesis, diagnostic evaluation, and therapeutic modalities available for common malignant hematological diseases.
2. Explain the pathogenesis, diagnostic evaluation, and therapeutic modalities available for common solid tumor malignancies.
3. Integrate guideline-based treatments into clinical practice while personalizing care appropriately for the patient.
4. Organize new therapeutic and diagnostic approaches into clinical practice as appropriate.

Target Audience

Specialties - Hematology, Oncology

Professions - Non-Physician, Nurse, Nurse Practitioner, Physician, Physician Associate

Accreditation

Credit Designation: The University of Washington School of Medicine designates this live activity for a maximum of 36.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification (MOC) Credits: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 36.75 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For more information please visit the official event page.